Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00241176 · ClinicalTrials.gov registry record · Phase 4
Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder
A Phase 4 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT00241176 is a Phase 4 study that has completed, run by NYU Langone Health. The registered enrollment target is 11 participants.
The verdict
NCT00241176, a Phase 4 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Abilify will reduce tics (repetitive, uncontrollable movements or vocalizations) in children and adolescents ages 7-18 with Tourette's Disorder (TD) or a chronic motor tic disorder (either repetitive, uncontrollable movements or vocalizations).
Interventions
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2005-09 |
| Est. Completion | 2010-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00241176
The ClinicalTrials.gov registry entry for NCT00241176 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aripiprazole is the first listed.
NCT00241176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00241176 about?
NCT00241176 is a clinical study titled "Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder". The purpose of this study is to determine if Abilify will reduce tics (repetitive, uncontrollable movements or vocalizations) in children and adolescents ages 7-18 with Tourette's Disorder (TD) or a chronic motor tic disorder (either repetitive, uncontrollable movements or vocalizations).
What is the current status of trial NCT00241176?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2005-09. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00241176?
The interventions under investigation include: Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00241176?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.